| Raquel M Villavicencio, MD | |
|
11911 N Meridian St Ste 125, Carmel, IN 46032 | |
| (317) 620-1006 | |
| (317) 621-1010 |
| Full Name | Raquel M Villavicencio |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 18 Years |
| Location | 11911 N Meridian St Ste 125, Carmel, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134338189 | NPI | - | NPPES |
| P01824828 | Other | IN | MEDICARE RR |
| 200946470 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 01066734A (Indiana) | Primary |
| 207R00000X | Internal Medicine | 01066734A (Indiana) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Hospital North | Indianapolis, IN | Hospital |
| Community Howard Regional Health Inc. | Kokomo, IN | Hospital |
| Community Hospital East | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Physicians Of Indiana Inc | 1759416662 | 1319 |
News Archive
Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).
Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc. today presented data from a Phase 2 study for the investigational drug buprenorphine HCl buccal film utilizing BDSI's patented BioErodible MucoAdhesive (BEMA) drug delivery technology.
Affymax, Inc. today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2012 for the review of the investigational agent peginesatide New Drug Application.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that its Board of Directors adopted a Stockholder Rights Plan. The rights plan is designed to discourage coercive or unfair takeover tactics and to provide fair and equal treatment for all stockholders of the Company in the event that an unsolicited offer is made to acquire the Company.
Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.
› Verified 6 days ago
| Entity Name | Community Physicians Of Indiana Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619105244 PECOS PAC ID: 1759416662 Enrollment ID: O20100317000717 |
News Archive
Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).
Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc. today presented data from a Phase 2 study for the investigational drug buprenorphine HCl buccal film utilizing BDSI's patented BioErodible MucoAdhesive (BEMA) drug delivery technology.
Affymax, Inc. today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2012 for the review of the investigational agent peginesatide New Drug Application.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that its Board of Directors adopted a Stockholder Rights Plan. The rights plan is designed to discourage coercive or unfair takeover tactics and to provide fair and equal treatment for all stockholders of the Company in the event that an unsolicited offer is made to acquire the Company.
Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Raquel M Villavicencio, MD 6626 E 75th St, Ste 500, Indianapolis, IN 46250-2805 Ph: () - | Raquel M Villavicencio, MD 11911 N Meridian St Ste 125, Carmel, IN 46032 Ph: (317) 620-1006 |
News Archive
Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).
Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc. today presented data from a Phase 2 study for the investigational drug buprenorphine HCl buccal film utilizing BDSI's patented BioErodible MucoAdhesive (BEMA) drug delivery technology.
Affymax, Inc. today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of March 27, 2012 for the review of the investigational agent peginesatide New Drug Application.
Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, announced today that its Board of Directors adopted a Stockholder Rights Plan. The rights plan is designed to discourage coercive or unfair takeover tactics and to provide fair and equal treatment for all stockholders of the Company in the event that an unsolicited offer is made to acquire the Company.
Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.
› Verified 6 days ago
Dr. Shelagh Anne Fraser, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 12174 N Meridian St Ste 300, Carmel, IN 46032 Phone: 317-688-9000 Fax: 317-680-9900 | |
Shania Grace Mayer, PA-C Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 10300 N Illinois St Ste 1100, Carmel, IN 46290 Phone: 317-944-0980 | |
Robert Mark Kinn, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 13806 Stone Dr, Carmel, IN 46032 Phone: 317-893-1900 | |
Olivia Ann Fondoble, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 13430 N Meridian St Ste 280, Carmel, IN 46032 Phone: 317-582-8030 | |
Dr. Peter Jerome Bustamante, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 13450 N Meridian St Ste 354, Carmel, IN 46032 Phone: 317-338-5100 | |
Thomas L Hutchinson, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 11725 Illinois Street, Suite 465, Carmel, IN 46032 Phone: 317-817-0010 Fax: 317-817-0012 | |
Chintan J Amin, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 11725 Illinois St Ste 325, Carmel, IN 46032 Phone: 317-688-5800 Fax: 317-688-5805 |